AstraZeneca PLC (AZN)
| Market Cap | 290.09B +39.0% |
| Revenue (ttm) | 60.44B +9.9% |
| Net Income | 10.39B +33.7% |
| EPS | 6.64 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 27.92 |
| Forward PE | 17.58 |
| Dividend | $3.20 (1.71%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 2,120,801 |
| Open | 188.22 |
| Previous Close | 189.75 |
| Day's Range | 186.45 - 189.08 |
| 52-Week Range | 134.90 - 212.71 |
| Beta | 0.22 |
| Analysts | Strong Buy |
| Price Target | 224.49 (+20.03%) |
| Earnings Date | Apr 29, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $224.49, which is an increase of 20.03% from the latest price.
News
Daiichi Sankyo, AstraZeneca’s Datroway approved in U.S to treat TNBC
Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Datroway has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer who are not…
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with ...
AstraZeneca and Daiichi Sankyo’s Enhertu recommended in EU by CHMP in HER2
The company states: “AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union as a monotherapy for the treatment of adult...
AstraZeneca’s Camizestrant recommended for approval in EU by CHMP
The company states: “AstraZeneca’s (AZN) camizestrant in combination with a cyclin-dependent kinase 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been recommended for approval in the Euro...
AstraZeneca announces new data from portfolio, pipeline at ASCO meeting
AstraZeneca (AZN) announces new data across its portfolio and pipeline at the American Society of Clinical Oncology, ASCO, Annual Meeting, 29 May to 2 June 2026. EMERALD-3: Phase III trial…
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause of death and transform outcomes for people living with rare diseases with new data across its divers...
EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug
A European Medicines Agency committee said on Friday it has adopted a positive opinion of AstraZeneca's experimental breast cancer drug, camizestrant.
US Supreme Court rebuffs pharma challenge to Biden-era drug price
The U.S. Supreme Court declined on Monday to hear a pharmaceutical industry challenge to a plan to curb Medicare drug prices adopted during Democratic former President Joe Biden's administration that...
Jefferies says Baxfendy approval may be incrementally constructive for Mineralys
Jefferies analyst Dennis Ding notes that AstraZeneca’s (AZN) Baxfendy was approved by the FDA as the first-ever aldosterone synthase inhibitor, adding that Baxfendy’s approval may be “incrementally co...
AstraZeneca announces U.S. approval for BAXFENDY in hypertension
AstraZeneca’s (AZN) BAXFENDY has been approved in the US as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive medications, to...
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combin...
AstraZeneca’s Baxfendy approved in U.S. for treatment of hypertension
AstraZeneca’s (AZN) Baxfendy has been approved in the US as a first-in-class aldosterone synthase inhibitor, ASI, for the treatment of hypertension in combination with other antihypertensive medicatio...
‘We Have Been Waiting… for Many Years’: AstraZeneca Stock (AZN) Drops despite Win for Potential Blockbuster Pill
AstraZeneca’s ($AZN) shares edged lower early Monday despite the British pharma giant securing approval for its Baxfendy (baxdrostat) blood pressure pill. The drug is seen as a blockbuster drug candid...
AstraZeneca Gets U.S. Approval for Hypertension Drug
The pharmaceutical company expects the drug Baxfendy to generate multibillion-dollar annual sales at its peak.
AstraZeneca's blood pressure drug wins U.S. approval
Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill baxdrostat had been approved in the United States, offering a new treatment option for millions of patients with uncontrolled h...
Daiichi Sankyo, AstraZeneca’s Enhertu approved by U.S. FDA
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) Enhertu has been approved by the US Food and Drug Administration, FDA, for both the neoadjuvant and adjuvant treatment of patients with HER2-positive ear...
AstraZeneca announces results from interim analysis of VOLGA Phase III trial
High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with IMFINZI in combination with neoadjuvant enfortumab vedotin demonstrated statisticall...
AstraZeneca announces results interim analysis of Volga Phase III trial
High-level results from a planned interim analysis of the Volga Phase III trial showed perioperative treatment with Imfinzi in combination with neoadjuvant enfortumab vedotin, EV, demonstrated statist...
AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial
AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to a surgery, showed significantly improved survival rate in patients with muscle-invasive bla...
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca
NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with A...
BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026
LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory ...
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat
Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely need...
AstraZeneca stock falls after FDA panel votes against new cancer drug
An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca's oral drug camizestrant intended for a type of breast cancer tumor, citing concerns around trial design. Astr...
AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote
The British pharmaceutical group said it would continue to work with U.S. regulators on a review of its breast-cancer candidate after the drug failed to get backing at a key advisory committee vote.
AstraZeneca shares drop after US regulatory panel votes against breast cancer drug
Shares of AstraZeneca fell 1.7% on Friday after an advisory panel for the U.S. Food and Drug Administration overnight voted against recommending the British drugmaker's experimental breas...